All > Covid

SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes for Symptomatic COVID-19 Infection

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Symptomatic COVID-19 Infection+2 MoreSARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing if SARS-CoV-2 specific cytotoxic T lymphocytes (CTLs), a type of immune cell, can help control the COVID-19 in cancer patients.

Eligible Conditions
  • Symptomatic COVID-19 Infection
  • Cancer
  • Blood Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
MET-4
1
Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
1
Coronavirus-specific T cell (CST)

Study Objectives

2 Primary · 8 Secondary · Reporting Duration: Up to 3 months post-infusion

At 28 days post-infusion
All-cause mortality
Proportion of subjects alive and free of respiratory failure
Month 3
Overall survival
Month 3
Relapse free survival (original malignancy)
Week 2
Response to cytotoxic T lymphocytes
Month 3
Assessment of feasibility
Cumulative incidence of coronavirus disease 2019 pneumonia resolution after therapy
Cumulative incidence of grade 2-4 or 3-4 graft versus host disease (GVHD), and chronic GVHD
Incidence of adverse events
Reconstitution of anti-virus immunity

Trial Safety

Safety Progress

1 of 3

Similar Trials

2
MET-4
1
Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
1
Coronavirus-specific T cell (CST)

Trial Design

1 Treatment Group

Treatment (SARS-COV-2 specific cytotoxic T cells)
1 of 1

Experimental Treatment

16 Total Participants · 1 Treatment Group

Primary Treatment: SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes · No Placebo Group · Phase < 1

Treatment (SARS-COV-2 specific cytotoxic T cells)
Biological
Experimental Group · 1 Intervention: SARS-CoV-2 Antigen-specific Cytotoxic T-lymphocytes · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 months post-infusion

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,805 Previous Clinical Trials
1,790,518 Total Patients Enrolled
David Marin, MDPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
94 Total Patients Enrolled
Katy RezvaniPrincipal InvestigatorM.D. Anderson Cancer Center
2 Previous Clinical Trials
100 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are of childbearing potential and are willing to use an effective contraceptive measure while on study.
You have a solid malignancy and you have received chemotherapy, targeted therapy or immunotherapy within 6 months prior enrollment and you are not planned to receive additional chemotherapy, targeted therapy or immunotherapy for at least 6 weeks after the infusion.
Patients with hematological malignancies who have been in MRD-negative CR for more than 3 years and have a peripheral blood CD4 count < 200 x 10^9cells/liter.
You have a peripheral blood CD4 count of < 200 x 10^9 cells/liter.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top